拉米夫定治疗乙型肝炎肝硬化失代偿期的临床观察。
Clinical Observation of Lamivudine for Decompensated Cirrhosis Resulting from Chronic Hepatitis b.
拉米夫定原研药曾被欧洲部分企业控制，价格昂贵。
Lamivudine have been the original drug research enterprise to control parts of Europe, which is very expensive.
目的探讨苦参碱和拉米夫定治疗活动性肝硬化的临床疗效。
Objective to investigate the clinical therapeutic effect of matrine and lamivudine on the active hepatocirrhosis.
结论：临床应重视拉米夫定的不良反应，以确保用药安全。
CONCLUSION: Great importance should be attached to ADRs of lamivudine to ensure the safety of drug use in clinic.
说明拉米夫定治疗不能阻断所有新生儿围产期的母婴传播。
Lamivudine therapy might not prevent perinatal transmission of HBV infection in every newborn.
另外历史对照组116例患者未接受预防性拉米夫定口服。
The historical control group consisted of 116 patients who underwent chemotherapy without lamivudine treatment.
目的：观察拉米夫定在预防HBV再激活的有效性与安全性。
Objective: To investigate effectiveness and safety of lamivudine in preventing the reactivation of HBV.
结论拉米夫定治疗儿童慢性乙型肝炎是安全有效的药物之一。
Conclusion Lamivudine is a safe and effective medicine in treating children with chronic hepatitis B.
目的：探讨使用拉米夫定后产生不良反应的一般规律和特点。
Objective: To discuss the general rules and characteristics of adverse drug reactions (ADRS) of lamivudine.
旨在提高和保持拉米夫定在慢性乙型肝炎抗病毒治疗的效果。
The objective is to improve and maintain the antiviral treatment efficacy of lamivudine in chronic hepatitis B.
预防性短期使用拉米夫定预防HBV再激活是有效及安全的。
It is effective and safe that preventing HBV reactivation by lamivudine in a short term.
目的：探讨乙肝病毒(HBV)基因型与拉米夫定疗效的关系。
Objective: To investigate the relationship between HBV genotypes and therapeutic effects of Lamivudine.
对拉米夫定耐药的慢性乙肝患者面临着病情恶化甚至死亡的危险。
Patients with chronic hepatitis B developing lamivudine resistance are at high risk of disease progression and death.
结果：拉米夫定不良反应临床表现多种多样，以肝炎病情加重为主。
RESULTS: The adverse drug reactions (ADRs) of lamivudine clinical manifestation to be many and varied, by hepatitis condition aggravation primarily.
目的研究拉米夫定停药后慢性乙型肝炎复发病例的临床特点和相关因素。
Objective To investigate the cases of chronic hepatitis B relapse after lamivudine withdrawal, and to find clinical characteristics and related factors to them.
该书1992年由霍顿·米夫林公司出版后，夫妇二人受到的关注也与日俱增。
It was published by Houghton Mifflin in 1992, and brought them a new level of attention.
因此，有必要更好地界定拉米夫定单独使用或类似的疗法的潜在作用和局限性。
Therefore, there is a need for a better definition of the potential role and limitations of lamivudine or similar therapies, used alone.
二代拉米夫定的长期应用可以有效地抑制病毒多聚酶突变频繁的HBV发生复制。
Long-term treatment with the second-generation nucleoside analogue lamivudine (lam) efficiently inhibits HBV replication with frequent viral polymerase mutations.
目的观察拉米夫定治疗儿童慢性乙型肝炎的临床疗效及对乙肝病毒标志物的影响。
Objective To observe the clinic effect of lamivudine in children with chronic hepatitis B and its influence of HBV markers.
结果：中药联合拉米夫定治疗慢性乙型肝炎能提高临床疗效，优于单用拉米夫定。
Results: Chinese medicine is effective in treating chronic hepatitis b, especially combined with Lamivudine.
然而，在拉米夫定的治疗过程中，并没有有效的血清标志物能预测变异的早期发生。
However, there is no useful serum marker that can predict early emergence of mutants during LAM therapy.
目的：评价拉米夫定在乙型肝炎病毒（HBV）感染者治疗中的临床疗效和安全性。
OBJECTIVE: To evaluate the clinical efficacy and safty of lamivudine in treatment of patients with HBV infections.
目的观察拉米夫定联合氧化苦参碱对抗慢性乙型肝炎(乙肝)肝纤维化的临床疗效。
Objective To observe the clinical effect of both oxymatrine and lamivudine on hepatic fibrosis induced by chronic hepatitis b.
目的研究复方牛胎肝提取物联合拉米夫定对慢性乙型病毒性肝炎患者肝纤维化的影响。
Objective To study the effect of compound fetal bovine liver extract tablets in combination with lamivudine on hepatic fibrosis in patients with chronic hepatitis B.
结论：服用拉米夫定一定严格把握治疗基线，选择最佳治疗时机，这是提高疗效的关键。
Conclusions: ALT base line must be taken into consideration when lamivudine treatment is employed and choosing the optimal treatment opportunity was the key to enhancing efficacy.
结论：YMDD变异后停用拉米夫定的患者将冒很大风险，容易导致肝功能肝功能衰竭。
Conclusion: Patients who withhold lamivudine after YMDD mutation will run great risks, which may lead to hepatic failure.
目的确定乙型肝炎病毒（HBV）基因型在山东地区的分布及拉米夫定抗病毒疗效的影响。
Objective To ascertain the distribution of HBV genotypes in Shandong province and its relationship with the antiviral effect of lamivudine.
目的定量分析拉米夫定治疗不同时期耐药突变的变化规律，为及时调整治疗方案提供依据。
Objetive to analysis the regulation of lamivudine-resistant mutations quantitatively in the different therapeutic periods, and to provide the evidences for therapeutic regimen adjustment.
目的评估妊娠晚期应用拉米夫定联合主被动免疫对于阻断HBV母婴传播的疗效及安全性。
Objective To evaluate the efficacy and safety of lamivudine treatment and active-passive immunization during the last trimester of pregnancy in preventing intrauterine HBV infection.
拉米夫定比常规药物更具有减轻局部炎性细胞因子浸润、分泌和促进肝细胞功能恢复的作用。
Lamivudine may also have higher down-regulate inflammatory infiltration and secretion in local site caused by chemotactic cytokines and promotional effect on the recovery of liver function.
应用推荐